Five points to remember if FDA issues a Form 483

October 2, 2020 Becky Hurt

Share this Article
Facebook
Twitter
Email
LinkedIn

Our regulatory compliance consulting team includes over 80 former regulators and
inspectors who, alongside seasoned industry experts, help clients mitigate compliance
risks, manage remediations, and restore confidence.
Contact info@parexel.com or visit parexel.com/compliance to learn more.

How Fair is FDA in Enforcement? Stacking Up the Agency Against a New Memo from the White House

The impact of COVID-19 on clinical trials in rare disease and oncology

Other content in this Stream

3:04

Patient engagement: Being heard

Parexel’s Leslie DeVos and Katie Connelly both VP’s of Regulatory & Access have a heartfelt conversation with Lennie & Denny Woods, Parents & Co-Founders of Sara’s Cure (https://sarascure.org/), of th

Watch Video

Drug Development for Rare Disease and Oncology During the COVID-19 Pandemic

Five points to remember if FDA issues a Form 483

Previous Article

Next Article

Other content in this Stream

Parexel’s Leslie DeVos and Katie Connelly both VP’s of Regulatory & Access have a heartfelt conversation with Lennie & Denny Woods, Parents & Co-Founders of Sara’s Cure (https://sarascure.org/), of th

Despite the best efforts of the pandemic, the FDLI delayed but did not cancel its annual meeting for 2020 and hosted the event through a virtual platform. In this blog, I’ll walk through the...

No Content.

As the pandemic clearly revealed, there is an urgent need for a more cohesive, coordinated approach to streamline global regulatory guidelines to ensure patients have faster access to new and...

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Parexel’s Chief...

On August 19, FDA published the final guidance Manufacturing, Supply Chain, and Drug and Biological Product Inspections During COVID-19 Public Health Emergency Questions and Answers. You can find...

On August 6, 2020 the president of the United States signed an Executive Order (EO) on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States. The...

Conducting clinical trials during the COVID-19 pandemic has produced many challenges globally. The initiation, conduct, implementation and completion of a trial during this time requires special...

Among biotech companies, a primary concern is how to establish a clinical strategy for scientific and commercial success at the earliest stage. In that respect, regulatory considerations figure...

As global regulatory agencies are preparing to return to on-site inspections1, industry needs to be ready. With the continued threat of COVID-19, the way inspections will be performed and hosted...

On March 27, 2020 the president of the United States signed into law the Coronavirus Aid, Relief and Economic Security (CARES) Act in response to the emerging pandemic (a copy of the public law...

On June 23, 2020 the European Medicines Agency (EMA) released a report on lessons learned from the presence of N-nitrosamine impurities in angiotensin II receptor blocker drugs. You can find a...

There have been two recent activities from the U.S. Food and Drug Administration (FDA) that provide industry more insight into how the agency is approaching product and manufacturing quality...